Stocks of Moderna Inc (NASDAQ:MRNA) traded higher last session on Wall Street, down -3.45% to $147.92.
MRNA stock price is now 26.91% away from the 50-day moving average and 47.50% away from the 200-day moving average. The market capitalization of the company currently stands at $56.69B.
Top 5 Artificial Intelligence Stocks to Buy for 2024
By now, you're well aware of the artificial intelligence boom. You know Big Tech has been investing billions of dollars into it.
According to Next Move Strategy Consulting, the AI market – currently valued at about $100 billion – cold grow twenty-fold by 2030 to more than $2 trillion. That means you may want to strongly consider these top AI stocks. Get our free report, "Top 5 AI Stocks to Buy in 2024."
Click here to automatically get the our FREE Report & Special Offer "5 Best AI Stocks to Invest In"
Sponsored
With the price target enhanced from $75 to $86, HSBC Securities Downgraded its rating from Hold to Reduce for Moderna Inc (NASDAQ: MRNA). On January 02, 2024, Oppenheimer Upgraded its previous ‘Perform’ rating to ‘Outperform’ on the stock keeping its target price maintained at $142, while ‘Canaccord Genuity’ rates the stock as ‘Hold’
In other news, Klinger Shannon Thyme, Chief Legal Officer sold 1,296 shares of the company’s stock on May 28 ’24. The stock was sold for $210,566 at an average price of $162.47. Upon completion of the transaction, the Chief Legal Officer now directly owns 10,623 shares in the company, valued at $1.57 million. An SEC document containing details of the transaction can be found on the SEC’s website. On May 28 ’24, Chief Financial Officer Mock James M sold 648 shares of the business’s stock. A total of $105,283 was realized by selling the stock at an average price of $162.47. This leaves the insider owning 5,726 shares of the company worth $0.85 million. A total of 12.12% of the company’s stock is owned by insiders.
During the past 12 months, Moderna Inc has had a low of $62.55 and a high of $170.47. As of last week, the company has a debt-to-equity ratio of 0.10, a current ratio of 4.03, and a quick ratio of 3.91. The fifty day moving average price for MRNA is $116.5572 and a two-hundred day moving average price translates $100.28552 for the stock.
The latest earnings results from Moderna Inc (NASDAQ: MRNA) was released for 2024-03-31. According to the Biotechnology Company, earnings per share came in at -3.62, beating analysts’ expectations of -4.04 by 0.42. This compares to $0.20 EPS in the same period last year. The net profit margin was -116.00% and return on equity was -37.68% for MRNA. The company reported revenue of $167.0 million for the quarter, compared to $1.86 billion a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue fell -91.03 percent. For the current quarter, analysts expect MRNA to generate $135.92M in revenue.
